Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Primary Dysautonomias 1Pancreatic Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1High Risk Prostate Cancer 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Receptors, Androgen × Clear all
NCT02138383 2021-08-17

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
25 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡